Venetoclax
Showing 476 - 485 of 485
Mantle Cell Lymphoma Trial in France, United Kingdom (Ibrutinib + GA101 +GDC-0199)
Active, not recruiting
- Mantle Cell Lymphoma
- Ibrutinib + GA101 +GDC-0199
-
Angers, France
- +8 more
Mar 11, 2020
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (CC-122, Ibrutinib, Obinutuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- CC-122
- +2 more
-
La Jolla, California
- +23 more
Aug 20, 2021
Multiple Myeloma Trial in Darlinghurst, Fitzroy, Prahran (Venetoclax, ABBV-838, Dexamethasone)
Withdrawn
- Multiple Myeloma
- Venetoclax
- +2 more
-
Darlinghurst, Australia
- +2 more
Jun 1, 2017
Chronic Lymphocytic Leukemia Electronic Patient Reported
Completed
- CLL
- Carevive CPS
-
Tampa, FloridaMoffitt Cancer Institute
Aug 23, 2019
Cancer Trial in New York, Columbus (SNX-5422 plus ibrutinib)
Terminated
- Cancer
- SNX-5422 plus ibrutinib
-
New York, New York
- +1 more
Feb 21, 2019
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma Trial in United States (Duvelisib, Venetoclax)
Withdrawn
- Chronic Lymphocytic Leukemia
- +2 more
- Duvelisib
- Venetoclax
-
Tucson, Arizona
- +9 more
Jul 22, 2016
Relapsed/Refractory Non-Hodgkin's Lymphoma Trial ([14C]ABT-199 (GDC-0199))
Withdrawn
- Relapsed/Refractory Non-Hodgkin's Lymphoma
- [14C]ABT-199 (GDC-0199)
- (no location specified)
Aug 12, 2014